Dr. Carl June Receives Leadership in Personalized Medicine Award
Personalized Medicine Coalition award recognizes new era in precision medicine with treatments characterized by ability to alter molecular characteristics of patients’ own cells.
Read moreResearch Lab Update
Update March 18: Message to PLM Research Faculty: NIH COVID-19 announcements and PSOM-mandated lab ramp-down.
Read moreResearch Lab Update
Update March 16: Message to PLM Research Faculty regarding lab ramp-down as mandated by PSOM leadership.
Read moreCRISPR-engineered T cells in Patients with Refractory Cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published in Science by researchers from the Abramson Cancer Center.
Read moreCRISPR-engineered T cells in patients with refractory cancer
Genetically-edited immune cells can persist, thrive, and function months after a cancer patient receives them, according to new data published by researchers from the Abramson Cancer Center.
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
Penn study shows potential of interferon pathway as biomarker, therapeutic target
